Additional systematic reviews encompassing both randomized and non-randomized studies have similarly indicated that incretin therapy, that is, DPP-4 inhibitors, does not seem to be correlated with an elevated risk of pancreatitis in individuals with T2D (Li et al., 2014). This evidence concerns the gene GCG and pancreatitis.